This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (6)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in JAMA  Topic Collections  • Cardiovascular System  • Cardiovascular Disease/ Myocardial Infarction  • Alert me on articles by topic  Social Bookmarking   What's this?

Carl J. Pepine, MD

JAMA. 2004;292:2271-2273.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

The number of persons with coronary artery disease (CAD) is increasing dramatically, with more patients surviving myocardial infarction (MI), the aging of the population, and the increasing prevalence of diabetes, obesity, and inactivity.¹ As a result, deaths from cardiovascular disease have increased about 2.5% per year over the past decade.² Yet there is a paucity of prospective randomized trial data on the relative impact of various drugs and blood pressure levels on adverse outcomes in patients with CAD. This information is critical to current management of these patients for many reasons. Past experiences have demonstrated that patients with myocardial ischemia may react differently to many drugs that otherwise appear safe (eg, nifedipine, phosphodiesterase inhibitors, antiarrhythmic agents, rofecoxib) and reducing blood pressure in patients with CAD is very complex. To this end, 2 large randomized clinical trials^3-4 examining blood pressure treatment in patients with CAD provide important . . . [Full Text of this Article]

Author Affiliation: Division of Cardiovascular Medicine, Department of Medicine, University of Florida College of Medicine, Gainesville.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLE

Effect of Antihypertensive Agents on Cardiovascular Events in Patients With Coronary Disease and Normal Blood Pressure: The CAMELOT Study: A Randomized Controlled Trial
Steven E. Nissen, E. Murat Tuzcu, Peter Libby, Paul D. Thompson, Magdi Ghali, Dahlia Garza, Lance Berman, Harry Shi, Ethel Buebendorf, Eric J. Topol, and for the CAMELOT Investigators
JAMA. 2004;292(18):2217-2225.
ABSTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Are Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers Especially Useful for Cardiovascular Protection?
Ong
J Am Board Fam Med 2009;22:686-697.
ABSTRACT | FULL TEXT  

Dogma Disputed: Can Aggressively Lowering Blood Pressure in Hypertensive Patients with Coronary Artery Disease Be Dangerous?
Messerli et al.
ANN INTERN MED 2006;144:884-893.
ABSTRACT | FULL TEXT  

A Simplified Approach to the Management of Non-ST-Segment Elevation Acute Coronary Syndromes
Gluckman et al.
JAMA 2005;293:349-357.
ABSTRACT | FULL TEXT  

Antihypertensive Therapy in Patients with Stable CAD
Journal Watch Cardiology 2004;2004:2-2.
FULL TEXT